Literature DB >> 2411251

Immunogenicity of an oil-emulsified Escherichia coli bacterin against heterologous challenge.

J E Gyimah, B Panigrapy, C F Hall, J D Williams.   

Abstract

Immunogenicity of an oil-emulsified Escherichia coli bacterin against heterologous challenge was investigated. In Expts. 1 and 2, chickens were vaccinated with E. coli serotype O1 bacterin and challenged with E. coli serotype O2 (Expt. 1) and O78 (Expt. 2). Positive control chickens were not vaccinated but challenged with E. coli serotype O2 or O78; unvaccinated unchallenged chickens served as negative controls. When challenged with E. coli serotype O2, unvaccinated chickens showed a higher morbidity than vaccinated chickens. There was no mortality in either group. Although average gross lesion scores were generally higher in the unvaccinated chickens, they were not significantly different (P greater than or equal to 0.05) from those in the vaccinated chickens. In Expt. 2, morbidity was slightly higher in the unvaccinated challenged chickens. No mortality occurred in either group. There was no significant difference (P greater than or equal to 0.05) between vaccinated and unvaccinated chickens in average gross lesion scores. In general, E. coli recovery was higher in the unvaccinated challenged chickens, being highest in the air sacs followed by the liver, heart blood, and pericardial sacs. There was no morbidity, mortality, or gross lesions in the unvaccinated unchallenged chickens. No E. coli was recovered from the tissues cultured. The results of these laboratory trials revealed that an oilemulsified monovalent E. coli bacterin did not protect chickens against other E. coli serotypes associated with colibacillosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411251

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  1 in total

1.  Outer membrane protein patterns mark clones of Escherichia coli O2 and O78 strains that cause avian septicemia.

Authors:  V Kapur; D G White; R A Wilson; T S Whittam
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.